🌍·1d agodiscovery
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Publisher
S
STT Info
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- STT Info
- Region
- Global
- Scope
- discovery
- Published
- September 9, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: STT Info
Scope: discovery
Related coverage
More related coverage
MarketBeat/5h ago
Best Biotech Stocks To Add to Your Watchlist - September 10th
Contemporary Pediatrics/5h ago
XOCOVA offers new post-exposure COVID-19 prevention option for adolescents
SRP Structured Products/5h ago
HSIL extends biotech index to Malaysia’s warrant market
Pharmaceutical Commerce/6h ago